CAS 943319-70-8
:Ponatinib
Description:
Ponatinib is a targeted therapy medication primarily used in the treatment of certain types of leukemia, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are resistant to other treatments. It is classified as a tyrosine kinase inhibitor, specifically designed to inhibit the BCR-ABL fusion protein, which is often responsible for the proliferation of cancer cells in these conditions. The chemical formula of ponatinib reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. It is characterized by its ability to cross the blood-brain barrier, making it effective for central nervous system involvement in leukemia. Ponatinib is administered orally and is known for its potential side effects, which can include cardiovascular issues, hypertension, and myelosuppression. Due to its potency and the risk of serious adverse effects, its use is typically reserved for patients who have not responded to other therapies. Monitoring and management of side effects are crucial during treatment with ponatinib.
Formula:C29H27F3N6O
InChI:InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
InChI key:InChIKey=PHXJVRSECIGDHY-UHFFFAOYSA-N
SMILES:C(#CC1=CC(C(NC2=CC(C(F)(F)F)=C(CN3CCN(C)CC3)C=C2)=O)=CC=C1C)C=4N5C(=NC4)C=CC=N5
Synonyms:- 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide
- Ap 24534
- Ap24534
- Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-
- Iclusig
- Ponatinib
- AP24534(Ponatinib)
- 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
- Ponatinib hybrochloride
- AP24534 hybrochloride
- Ponatinib (AP24534)
- 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide Ponatinib(AP24534) AP 24534
- Ponatinib (with 4 ints.)
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
Ponatinib, Free Base
CAS:<p>Ponatinib, Free Base</p>Formula:C29H27F3N6OPurity:98%Color and Shape: solidMolecular weight:532.56g/molPonatinib
CAS:<p>Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively</p>Formula:C29H27F3N6OPurity:98% - 99.60%Color and Shape:SolidMolecular weight:532.56Ponatinib
CAS:Formula:C29H27F3N6OPurity:≥ 98.0%Color and Shape:White or off-white powder or crystalsMolecular weight:532.56Ponatinib
CAS:Controlled Product<p>Applications Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor It is a COVID19-related research product.<br>References (1) Poch, M. M., et al.: Expert Rev Hematol. 9, 923 (2016) (2) Shamroe, C. L. and Comeau, J. M. Ann Pharmacother. 47, 1540 (2013)(3) Oaxaca, D. M., et al.: Tumour Biol. 37, 12643 (2016)<br></p>Formula:C29H27F3N6OColor and Shape:Off-WhiteMolecular weight:532.56Ponatinib
CAS:<p>BCR-ABL1 tyrosine kinase inhibitor</p>Formula:C29H27F3N6OPurity:Min. 95%Color and Shape:PowderMolecular weight:532.56 g/molPonatinib Glucuronide
CAS:Controlled ProductFormula:C35H35F3N6O7Color and Shape:NeatMolecular weight:709.692





